Idiopathic pulmonary fibrosis (IPF) is the most common fibrotic form of idiopathic diffuse lung
disease. Due to limited treatment options, IPF patients suffer from poor survival. About ten …

Idiopathic inflammatory myopathies are a group of autoimmune diseases with a broad
spectrum of clinical presentations, primarily characterised by immune-mediated muscle …

No effective treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD)
exists. Numerous evidences support the importance of adaptive immunity in SSc-ILD. A …

Interstitial lung disease (ILD) is a large and heterogenous group of diseases, primarily
manifesting in the distal bronchoalveolar space. Some ILDs have identifiable causes or …

Current Opinion in Pulmonary Medicine Log in or Register Subscribe to journalSubscribe
Get new issue alertsGet alerts Secondary Logo Journal Logo Advanced Search Toggle …

Lysophosphatidic acid (LPA)-mediated activation of LPA receptor 1 (LPAR1) contributes to
the pathophysiology of fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and …

Introduction Progressive pulmonary fibrosis (PPF) is a manifestation of a heterogenous
group of underlying interstitial lung disease (ILD) diagnoses, defined as non-idiopathic …

ABSTRACT Introduction Systemic sclerosis (SSc) is a chronic autoimmune rheumatic
disease characterized by microvascular alterations, immunopathology, and widespread …

Extract Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and fatal fibrotic lung
disease of unknown cause [1]. Other types of pulmonary fibrosis may exhibit a phenotype of …

Introduction Idiopathic inflammatory myopathies (IIM) represent a rare and heterogenous
group diseases, and their treatment is not fully defined yet. According to previous small case …